SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Arcolab skyrockets on selling 94% stake in Ascent Pharmahealth

24 Jan 2012 Evaluate

Strides Arcolab is currently trading at Rs. 481.00, up by 73.65 points or 18.08% from its previous closing of Rs. 407.35 on the BSE.

The scrip opened at Rs. 410.90 and has touched a high and low of Rs. 488.80 and 407.00 respectively. So far 459047 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 488.80 on 24-Jan-2012 and a 52 week low of Rs. 276.25 on 22-Aug-2011.

Last one week high and low of the scrip stood at Rs. 488.80 and Rs. 377.05 respectively. The current market cap of the company is Rs. 2459.26 crore.

The promoters holding in the company stood at 28.42% while Institutions and Non-Institutions held 54.49% and 17.09% respectively.

Strides Arcolab, the Indian drug maker has sold its 94% stake in Ascent Pharmahealth, its subsidiary with operations in Australia and Southeast Asia, to Watson Pharmaceuticals, Inc. As part of the transaction, Watson also acquired the remaining 6% shareholding associated with Dennis Bastas, CEO of Ascent. The transaction was signed and closed simultaneously. The cash offer from Watson values Ascent at an enterprise value of Aus $375 million.

Ascent is a top five genetic pharmaceutical company in Australia and is present across several countries in Southeast Asia, including Singapore where it is the leading generic pharmaceutical company.

Watson is an integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women’s Health.

Strides Arcolab is a global pharmaceuticals headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceuticals products with an emphasis on sterlite injectables.

Strides Pharma Scien Share Price

1000.70 6.80 (0.68%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×